Literature DB >> 26752401

Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma: A Clinicopathologic Study of 37 Cases From a Single Institution.

Hari P Dhakal1, Jesse K McKenney, Li Yan Khor, Jordan P Reynolds, Cristina Magi-Galluzzi, Christopher G Przybycin.   

Abstract

Clear cell papillary renal cell carcinoma (CCPRCC) was recently included in the International Society of Urological Pathology Vancouver Classification of Renal Neoplasia as a subtype of RCC that is morphologically, immunohistochemically, and genetically distinct from both clear cell renal cell carcinoma (CCRCC) and papillary renal cell carcinoma. In our clinical practice we have observed tumors with overlapping histologic features of CCPRCC and CCRCC; therefore, our aim was to describe the morphologic, immunohistochemical, and clinical characteristics of these tumors. We examined a large series of consecutive nephrectomies diagnosed as CCRCC and found 37 tumors with morphologic overlap between CCRCC and CCPRCC, identifying 2 patterns. Pattern 1 tumors (N=19) had areas diagnosable as CCRCC admixed with foci having a prominent linear arrangement of nuclei away from the basement membrane imparting a resemblance to CCPRCC; however, other morphologic features commonly seen in CCPRCC (such as branching acini and cystic spaces with papillary tufts) were not typical and, when present, were focal or poorly developed. Pattern 2 (N=18) tumors had 2 discrete areas, one area with an appearance strongly resembling CCPRCC and the other with higher grade nuclei and features diagnosable as CCRCC, sometimes including rhabdoid differentiation, sarcomatoid differentiation, necrosis, and high-stage disease. Four (21%) of the pattern 1 tumors had grade 3 nuclei in the CCRCC-like areas, and 4 were high stage (pT3a). Of the 16 immunostained pattern 1 tumors, all expressed cytokeratin 7 (CK7) at least focally in the CCPRCC-like areas, strongly and diffusely in 9 (56%) cases; 12 (75%) showed negative to focal and/or weak CK7 expression in the CCRCC-like areas. CD10, α-methylacyl-CoA-racemase, high-molecular-weight cytokeratin, and carbonic anhydrase IX (CA IX) had no significant differential expression between these foci. No cup-like staining pattern was seen with CA IX. Two (11%) patients with pattern 1 tumors developed metastases, and 1 (5%) subsequently died of disease. Eleven (61%) pattern 2 cases had the International Society of Urological Pathology grade 3 nuclei in the CCRCC-like areas, and 7 (39%) were grade 4 (4 of these cases had rhabdoid features; 1 was also sarcomatoid). Of the 16 immunostained pattern 2 tumors, 8 (50%) showed strong diffuse CK7 expression in the CCPRCC-like areas, and 9 (56%) showed complete lack of CK7 expression in the CCRCC-like areas. CD10, α-methylacyl-CoA-racemase, and high-molecular-weight cytokeratin did not have significant differential expression. Membranous expression of CA IX, typically strong and diffuse, was identified in both the CCPRCC-like and CCRCC-like areas in all cases tested (with a cup-like pattern at least focally in the CCPRCC-like areas of 10 [63%] pattern 2 cases). Five (28%) patients with pattern 2 tumors had distant metastases, 3 (17%) of whom subsequently died of disease. Renal cell carcinomas with areas resembling both CCRCC and CCPRCC occur. Some can have high-grade and high-stage foci, and aggressive clinical outcomes are seen. Given this malignant potential, we would presently diagnose such cases as CCRCC. These 2 patterns of renal neoplasia underscore the need for caution in diagnosing CCPRCC on limited sampling, reserving the diagnosis for those tumors that strictly fulfill both morphologic and immunohistochemical criteria.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26752401     DOI: 10.1097/PAS.0000000000000583

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

Review 1.  The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome.

Authors:  Francesco Massari; Chiara Ciccarese; Ondrej Hes; Michal Michal; Anna Caliò; Michelangelo Fiorentino; Francesca Giunchi; Alessandro D'Amuri; Francesca Sanguedolce; Roberto Sabbatini; Annalisa Guida; Andrea Ardizzoni; Camillo Porta; Roberto Iacovelli; Giampaolo Tortora; Luca Cima; Cinzia Ortega; Alberto Lapini; Guido Martignoni; Matteo Brunelli
Journal:  Pathol Oncol Res       Date:  2017-07-10       Impact factor: 3.201

2.  Prognostic Factors for Renal Cell Carcinoma Subtypes Diagnosed According to the 2016 WHO Renal Tumor Classification: a Study Involving 928 Patients.

Authors:  Levente Kuthi; Alex Jenei; Adrienn Hajdu; István Németh; Zoltán Varga; Zoltán Bajory; László Pajor; Béla Iványi
Journal:  Pathol Oncol Res       Date:  2016-12-28       Impact factor: 3.201

3.  Vascular architectural patterns in clear cell renal cell carcinoma and clear cell papillary renal cell carcinoma.

Authors:  Sofia Canete-Portillo; Maria Del Carmen Rodriguez Pena; Dezhi Wang; Diego F Sanchez; George J Netto; Cristina Magi-Galluzzi
Journal:  Virchows Arch       Date:  2021-10-05       Impact factor: 4.064

4.  New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.

Authors:  Kiril Trpkov; Ondrej Hes; Sean R Williamson; Anthony J Gill; Adebowale J Adeniran; Abbas Agaimy; Reza Alaghehbandan; Mahul B Amin; Pedram Argani; Ying-Bei Chen; Liang Cheng; Jonathan I Epstein; John C Cheville; Eva Comperat; Isabela Werneck da Cunha; Jennifer B Gordetsky; Sounak Gupta; Huiying He; Michelle S Hirsch; Peter A Humphrey; Payal Kapur; Fumiyoshi Kojima; Jose I Lopez; Fiona Maclean; Cristina Magi-Galluzzi; Jesse K McKenney; Rohit Mehra; Santosh Menon; George J Netto; Christopher G Przybycin; Priya Rao; Qiu Rao; Victor E Reuter; Rola M Saleeb; Rajal B Shah; Steven C Smith; Satish Tickoo; Maria S Tretiakova; Lawrence True; Virginie Verkarre; Sara E Wobker; Ming Zhou
Journal:  Mod Pathol       Date:  2021-03-04       Impact factor: 8.209

5.  Primary Renal Carcinoid with Bilateral Multiple Clear Cell Papillary Renal Cell Carcinomas.

Authors:  Daniel A Anderson; Maria S Tretiakova
Journal:  Case Rep Pathol       Date:  2017-05-23

Review 6.  Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review.

Authors:  Alessia Cimadamore; Liang Cheng; Marina Scarpelli; Francesco Massari; Veronica Mollica; Matteo Santoni; Antonio Lopez-Beltran; Rodolfo Montironi; Holger Moch
Journal:  Transl Androl Urol       Date:  2021-03

7.  The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management.

Authors:  Stanley Weng; Renzo G DiNatale; Andrew Silagy; Roy Mano; Kyrollis Attalla; Mahyar Kashani; Kate Weiss; Nicole E Benfante; Andrew G Winer; Jonathan A Coleman; Victor E Reuter; Paul Russo; Ed Reznik; Satish K Tickoo; A Ari Hakimi
Journal:  Eur Urol       Date:  2020-10-10       Impact factor: 20.096

8.  Renal Cell Carcinoma with Clear Cell Papillary Features: Perspectives of a Differential Diagnosis.

Authors:  Áron Somorácz; Levente Kuthi; Tamás Micsik; Alex Jenei; Adrienn Hajdu; Brigitta Vrabély; Erzsébet Rásó; Zoltán Sápi; Zoltán Bajory; Janina Kulka; Béla Iványi
Journal:  Pathol Oncol Res       Date:  2019-10-26       Impact factor: 3.201

9.  Clinical features and survival analysis of clear cell papillary renal cell carcinoma: A 10-year retrospective study from two institutions.

Authors:  Yiqiu Wang; Ying Ding; Jian Wang; Min Gu; Zengjun Wang; Chao Qin; Conghui Han; Hongxia Li; Xia Liu; Pengfei Wu; Guangchao Li
Journal:  Oncol Lett       Date:  2018-05-21       Impact factor: 2.967

Review 10.  Renal Cell Carcinoma in End-Stage Renal Disease: A Review and Update.

Authors:  Ziad M El-Zaatari; Luan D Truong
Journal:  Biomedicines       Date:  2022-03-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.